Results 201 to 210 of about 105,678 (295)

Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study. [PDF]

Kaohsiung J Med Sci, 2017
Huang WW, Hsieh KP, Huang RY, Yang YH.
europepmc   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016). [PDF]

Medchemcomm, 2017
Carullo G, Galligano F, Aiello F.
europepmc   +1 more source

Targeting WTAP/ROR1/WNT5A‐Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy

Advanced Science, EarlyView.
In hypoxic microenvironment, WNT5A is predominantly secreted by tumor‐associated macrophages. Hypoxia‐induced WTAP mediates ROR1 stability by m6A modifications in a HuR‐dependent manner in Glioma stem cells (GSCs). WNT5A activates the WNT pathway via ROR1 binding on GSCs, driving glioma‐derived endothelial cells (GDECs) differentiation.
Xiaoyong Chen, Bo Pang, Yun Liu, Jiangwei Wang, Lanhui Zheng, Yuzhou Chang, Yingxuan Sun, Haoyuan Sun, Huiyuan Chen, Jiawei Cai, Zanyi Wu, Qing Chang, Yongzhi Wang, Dezhi Kang, Tao Jiang, Ruichao Chai   +15 more
wiley   +1 more source

Multi‐Scale Mapping of Gene Expression from Whole‐slide Images for Identifying Phenotype‐Associated Subpopulations

Advanced Science, EarlyView.
BiSCALE: A pathology‐driven deep learning framework for multi‐scale gene expression prediction from whole‐slide images. It accurately infers bulk and near‐cellular spot‐level expression, links predictions to clinical phenotypes, identifies disease‐associated niches, and enables applications in risk stratification and cell‐identity annotation, providing
Hailong Zheng, Jiajing Xie, Luqi Wang, Hailong Xie, Tong Zhi, Yujia Guo, Bofeng Zhu, Dong Wang, Yu Chen   +8 more
wiley   +1 more source

Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. [PDF]

ACS Med Chem Lett, 2014
Radwan MF, Dalby KN, Kaoud TS.
europepmc   +1 more source

Dual‐Targeting Cuproptosis and Mitophagy via a Flavopiridol‐Copper Nanoplatform Potentiates Immunotherapy Against Uveal Melanoma

Advanced Science, EarlyView.
This study develops a GSH‐responsive nanoplatform, NP@Fla‐Cu, to co‐activate cuproptosis and excessive mitophagy in uveal melanoma. The nanoplatform enhances tumor‐specific copper delivery, depletes antioxidant defenses, and remodels the tumor immune microenvironment.
Hong Ren, Zhihong Deng, Sheng Lu, Jing Zhang, Wenbin Liu, Jia Tan   +5 more
wiley   +1 more source

Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. [PDF]

Ther Adv Drug Saf, 2017
Fanelli A, Ghisi D, Aprile PL, Lapi F.
europepmc   +1 more source

Pancancer Fine‐Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma

Advanced Science, EarlyView.
This study identifies mutation‐intolerant genes (MIGs), which are mutationally constrained in tumors despite normal‐tissue variability. Using miDriver, the authors pinpoint MIGs essential for tumor‐intrinsic fitness and immune evasion. Focusing on CHEK1, they show it drives tumor fitness and sculpts an immunosuppressive niche via the MIF–CD74 axis ...
Tao Wang, Hongyu Zhao, Xiaojie Sun, Yuqi Ding, Zhipeng Zhu, Xiaotong Yu, Rongyi Zhu, Dan Wang, Kailong Li, Yang Liu, Li‐Bin Wang, Xiaolu Zhao, Baojun Suo, Hongsen Bi, Peipei Zhang, Tong Liu, Fengbiao Mao   +16 more
wiley   +1 more source

Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments. [PDF]

Patient Prefer Adherence, 2016
Byun JH, Kwon SH, Lee JE, Cheon JE, Jang EJ, Lee EK.   +5 more
europepmc   +1 more source